Piper Sandler raised the firm’s price target on Arvinas (ARVN) to $20 from $16 and keeps an Overweight rating on the shares. The firm notes Arvinas ended 2025 with cash of $685.4M to fund operations into the second half of 2028. Arvinas will report ARV-102 data in Parkinson’s disease patients at Alzheimer’s and Parkinson’s Diseases Conference in March, initiate a Phase Ib study in Progressive Supranuclear Palsy in the first half of 2026, and may initiate a registrational trial in late 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
- Arvinas Earnings Call: High Science, Tight Cash
- Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts
- Arvinas price target raised to $11 from $9 at Wedbush
- Arvinas sees cash runway into 2H28